Equities Analysts Offer Predictions for Hologic Inc.’s Q1 2017 Earnings (HOLX)
Hologic Inc. (NASDAQ:HOLX) – Stock analysts at Leerink Swann issued their Q1 2017 EPS estimates for shares of Hologic in a research note issued on Thursday. Leerink Swann analyst R. Newitter forecasts that the brokerage will post earnings per share of $0.51 for the quarter. Leerink Swann has a “Buy” rating and a $46.00 price target on the stock. Leerink Swann also issued estimates for Hologic’s Q2 2017 earnings at $0.53 EPS, Q3 2017 earnings at $0.55 EPS, Q4 2017 earnings at $0.56 EPS, FY2018 earnings at $2.37 EPS and FY2019 earnings at $2.66 EPS.
Several other equities research analysts also recently issued reports on HOLX. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a report on Wednesday, September 28th. Barclays PLC raised Hologic from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $42.00 to $44.00 in a report on Friday, September 23rd. Piper Jaffray Cos. set a $44.00 price target on Hologic and gave the company a “hold” rating in a report on Sunday, August 28th. RBC Capital Markets reaffirmed a “sector perform” rating and set a $39.00 price target (up previously from $37.00) on shares of Hologic in a report on Monday, August 1st. Finally, Royal Bank Of Canada raised their price target on Hologic from $37.00 to $39.00 and gave the company a “sector perform” rating in a report on Monday, August 1st. Six equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $42.71.
Shares of Hologic (NASDAQ:HOLX) opened at 38.83 on Monday. The firm has a market cap of $10.77 billion, a P/E ratio of 42.81 and a beta of 1.00. The stock has a 50 day moving average of $38.32 and a 200 day moving average of $36.04. Hologic has a 52 week low of $31.84 and a 52 week high of $41.66.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.03. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The company had revenue of $717.40 million for the quarter, compared to the consensus estimate of $703.66 million. During the same quarter in the previous year, the company earned $0.43 EPS. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mizuho Asset Management Co. Ltd. boosted its position in Hologic by 89.9% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 3,313 shares of the company’s stock worth $115,000 after buying an additional 1,568 shares in the last quarter. J.Safra Asset Management Corp acquired a new position in Hologic during the second quarter worth about $115,000. Invictus RG boosted its position in Hologic by 577.0% in the second quarter. Invictus RG now owns 3,791 shares of the company’s stock worth $131,000 after buying an additional 3,231 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its position in Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares in the last quarter. Finally, Synovus Financial Corp boosted its position in Hologic by 35.6% in the second quarter. Synovus Financial Corp now owns 4,950 shares of the company’s stock worth $171,000 after buying an additional 1,300 shares in the last quarter. Hedge funds and other institutional investors own 94.51% of the company’s stock.
In related news, Director Nancy Leaming sold 6,221 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $36.04, for a total value of $224,204.84. Following the transaction, the director now owns 55,053 shares in the company, valued at $1,984,110.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.84% of the stock is owned by corporate insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.